



Shasun Chemicals And Drugs Limited
Regd. Office: 28, Sardar Patel Road, Guindy Chennai

Standalone Audited Financial Results for the year ended March 31, 2010

figures in Rs. lacs

Particulars	Quarter ended		Year ended	Year ended
	31.03.2010 (Audited)	31.03.2009 (Audited)	31.03.2010 (Audited)	31.03.2009 (Audited)
1.(a)Gross Sales/Income from Operations	15,138	12,137	54,715	47,783
	432	369	1,660	2,003
Net Sales/Income from Operations	14,706	11,768	53,055	45,780
(b) Other Operating Income	839	551	1,871	1,372
2. Expenditure				
a) (Increase)/Decrease in Stock in Trade	(1,464)	80	(1,159)	475
b) Consumption of Raw Materials	9,718	7,102	30,802	27,383
c) Purchase of traded goods	37	8	210	73
d) Employees Cost	1,072	1,106	4,893	4,617
e) Depreciation	644	676	2,602	2,691
g) Exchange (Gain) / Loss	1,029	1,772	3,285	5,619
h) Other Expenditure	3,490	1,792	10,984	8,993
Total Expenditure	14,526	12,536	51,617	49,851
3.Profit/(Loss) from Operations before Other Income, Interest & Exceptional Items	1,018	(217)	3,308	(2,699)
4. Other Income	51	140	313	153
5. Profit before Interest & Exceptional Items	1,069	(77)	3,621	(2,546)
6. Interest	324	446	1,592	1,222
7. Profit/(loss) from ordinary activities before tax	745	(523)	2,029	(3,768)
8. Tax expenses	(186)	(464)	(177)	(431)
9. Net Profit /(Loss) for the period	931	(59)	2,206	(3,337)
10.Paid up Equity Share Capital (Face Value Rs.2 per Share)	966	966	966	966
11.Reserves excluding revaluation reserve as per balance sheet of previous accounting year	19,856	18,215	19,856	18,215
12. Earnings Per Share				
(a) Basic	1.93	(0.12)	4.57	(6.91)
(a) Diluted	1.92	(0.12)	4.56	(6.90)
13.Aggregate of Non promoter shareholding				
a) Number of Shares	25,795,651	26,217,596	25,795,651	26,217,596
b) Percentage of Shareholding	53.39%	54.27%	53.39%	54.27%
Promoters and promoter group shareholding				
a) Pledged/Encumbered				
- Number of shares	5,345,000	1630000	5,345,000	1630000
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	23.73%	7.38%	23.73%	7.38%
- Percentage of shares (as a % of the total share capital of the Company)	11.06%	3.37%	11.06%	3.37%
b) Non-Encumbered				
- Numbers of shares	17,173,288	20466343	17,173,288	20466343
- Percentage of shares (as a % of the total shareholding promoter and promoter group)	76.27%	92.62%	76.27%	92.62%
- Percentage of shares (as a % of the total share capital of the Company)	35.55%	42.36%	35.55%	42.36%

Notes:

- The above results were reviewed by the Audit Committee at its meeting held on May 29, 2010 and approved by the Board of Directors at its meeting held on 30th May 2010
- The Board has recommended a dividend of 50% (Rs.1 per share) on the equity share of Rs.2/- each, subject to shareholder approval at the ensuing AGM
- The Company is exclusively in Pharmaceutical Business Segment
- Details of investor complaints for the quarter ended March 31, 2010: Beginning - Nil, Received - 3, Disposed off - 3 and Pending - NIL.
- Previous year / quarter figures are regrouped, reclassified to conform to current year / quarter classification.
- The audited standalone results of the company for the year ended March 31, 2010 is available at our website www.shasun.com

Place: Chennai
Date: 30.05.2010

By Order of the Board
N.Govindarajan
CEO & Managing Director.

Particulars	Quarter ended		Year ended	Year ended
	31.03.2010 (Audited)	31.03.2009 (Audited)	31.03.2010 (Audited)	31.03.2009 (Audited)
1.(a)Gross Sales/Income from Operations	21,266	22,568	80,172	77,293
Less: Excise duty	418	575	1,765	2,210
Net Sales/Income from Operations	20,848	21,992	78,407	75,083
(b) Other Operating Income	581	732	1,737	1,814
2.Total Expenditure				
a) (Increase)/Decrease in Stock in Trade	(2,957)	355	(1,795)	1,126
b) Consumption of Raw Materials	12,767	11,190	39,889	37,265
c) Release of Negative Goodwill	(6)	(20)	(81)	(79)
d) Purchase of traded goods	37	7	210	73
e) Employees Cost	3,246	4,388	14,007	17,193
f) Depreciation	951	1,061	3,786	3,813
g) Exchange (Gain) / Loss	1,358	2,860	4,296	7,116
h) Other Expenditure	4,591	5,557	18,783	20,945
Total Expenditure	19,987	25,398	79,095	87,452
3.Profit / (Loss) from Operations before Other Income, Interest & Exceptional Items	1,442	(2,673)	1,049	(10,555)
4. Other Income	48	640	313	721
5. Profit/(Loss) before Interest & Exceptional Items	1,490	(2,033)	1,362	(9,833)
6. Interest	655	748	2,892	2,098
7. Impairment loss for discontinued operations	(70)	2,208	(142)	2,208
8. Gain on sale of discontinued operation	(84)		1,587	
9. Profit/(Loss) from ordinary activities before tax	822	(4,989)	200	(14,140)
10. Tax expenses	(184)	(464)	(175)	(430)
11. Net Profit / (Loss) for the period	1,006	(4,525)	375	(13,710)
12.Paid up Equity Share Capital (Face Value Rs.2 per Share)	966	966	966	966
13.Reserves excluding revaluation reserve as per balance sheet of previous accounting year			10,344	9,965
14. Earnings Per Share				
(a) Basic	2.08	(9.37)	0.78	(28.37)
(a) Diluted	2.08	(9.35)	0.78	(28.33)
15.Aggregate of Non promoter shareholding				
a) Number of Shares	25,795,651	26,217,596	25,795,651	26,217,596
b) Percentage of Shareholding	53.39%	54%	53.39%	54.28%
16.Promoters and promoter group shareholding				
a) Pledged/Encumbered				
- Number of shares	5,345,000	1630000	5,345,000	1630000
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	23.73%	7.38%	23.73%	7.38%
- Percentage of shares (as a % of the total share capital of the Company)	11.06%	3.37%	11.06%	3.37%
b) Non-Encumbered				
- Numbers of shares	17,173,288	20466343	17,173,288	20466343
- Percentage of shares (as a % of the total shareholding promoter and promoter group)	76.27%	92.62%	76.27%	92.62%
- Percentage of shares (as a % of the total share capital of the Company)	35.55%	42.36%	35.55%	42.36%

Notes:

- 1) The above results were reviewed by the Audit Committee at its meeting held on May 29, 2010 and approved by the Board of Directors at the Board of Directors at its meeting held on 30th May 2010
- 2) The Board has recommended a dividend of 50% (Rs.1 per share) on the equity share of Rs.2/- each, subject to shareholder approval at the ensuing AGM
- 3) The Company is exclusively in Pharmaceutical Business Segment
- 4) Details of investor complaints for the quarter ended March 31, 2010: Beginning - Nil, Received - 3, Disposed off - 3 and Pending - NIL.
- 5) Previous year / quarter figures are regrouped, reclassified to conform to current year / quarter classification.
- 6) The audited standalone results of the company for the year ended March 31, 2010 is available at our website www.shasun.com

Place: Chennai
Date: 30.05.2010

By Order of the Board
N.Govindarajan
CEO & Managing Director.